From Startup Neon Therapeutics
CAMBRIDGE, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) — Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that it will host an investor event at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting, on November 9, 2018 at 6:00 p.m. ET in Washington, D.C.
In addition to presentations from management, the event will feature a keynote presentation from Siwen Hu-Lieskovan, M.D., Ph.D., Division of Hematology-Oncology, Department of Medicine, University of California, Los Angeles (UCLA).
To access the live webcast, please visit the Investor Relations section of Neon’s website at ir.neontherapeutics.com. A replay of the webcast will be posted shortly after the conference call and will remain available for 30 days following the presentation.
About Neon Therapeutics
Neon Therapeutics is a clinical-stage immuno-oncology company and a leader in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. Neon is using its neoantigen platform to develop both vaccine and T cell therapies, including NEO-PV-01, a clinical stage neoantigen vaccine for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of a subset of estrogen-receptor-positive breast cancer.For more information, please visit www.neontherapeutics.com.
Media Contact:Stephanie Simon, Ten Bridge Communicationsstephanie@tenbridgecommunications.com617-581-9333
Investor Contact:Will O’Connor, Stern Investor Relationswill@sternir.com212-362-1200
Source: Neon Therapeutics, Inc.
Please visit their site for more information: NeonTherapeutics.com